Fourth quarter and full year 2022 financial results and business update
Evaxion Biotech A/S - American Depositary Share (EVAX)
Company Research
Source: GlobeNewswire
Evaxion presented promising data from its Phase 1/2a clinical trial of EVX-02 in patients with late-stage melanoma at the 2023 AACR meetingEVX-03, a DNA-based personalized cancer vaccine, is expected to have a CTA filing in Q3 2023 and start a Phase 1 trial in solid tumor patients in Q4 2023Recent collaborations with Pantherna Therapeutics GmbH (utilizing PIONEER™) and ExpreS2ion Biotechnologies ApS (utilizing RAVEN™) highlight the broad utility of Evaxion’s differentiated AI platforms, which now includes the new ObsERVTM AI technology, which is designed to identify patient-specific viral targets from endogenous retroviruses (ERVs) known to be overexpressed in certain tumors$13 million in cash and equivalents as of December 31, 2022 is expected to fund operations into December 2023Evaxion to host a webcast and conference call today, April 27 at 8:30 am EDT COPENHAGEN, Denmark, April 27, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”)
Show less
Read more
Impact Snapshot
Event Time:
EVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVAX alerts
High impacting Evaxion Biotech A/S - American Depositary Share news events
Weekly update
A roundup of the hottest topics
EVAX
News
- Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 [Yahoo! Finance]Yahoo! Finance
- Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2GlobeNewswire
- Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual MeetingGlobeNewswire
- Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1GlobeNewswire
- Evaxion announce 2026 financial calendarGlobeNewswire
EVAX
Sec Filings
- 12/19/25 - Form 6-K
- 12/10/25 - Form 6-K
- 12/10/25 - Form 424B5
- EVAX's page on the SEC website